Allakos Reaches Corporate Endpoint with Concentra Acquisition
Published on 11/12/2025 at 08:23 | Redaktion boerse-global.de
The independent journey of Allakos as a publicly traded biopharmaceutical firm has concluded following its acquisition by Concentra Biosciences. Shareholders received a final distribution of $0.33 per share, a figure that stands in stark contrast to the stock’s 52-week peak of $1.55. Announced in April 2025, the transaction was finalized by mid-May, with approximately 81% of outstanding shares tendered at the agreed price.
The merger precipitated immediate executive changes. Dr. Robert Alexander stepped down from his role as Chief Executive Officer, accompanied by the departure of Chief Financial Officer Baird Radford. Management authority transferred entirely to Concentra’s leadership team. This transition marks the definitive end for investors:
- Trading Ceased: Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
